We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

89 hedge funds and large institutions have $170M invested in Tetraphase Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

218% more call options, than puts

Call options by funds: $1.7M | Put options by funds: $537K

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

21% more capital inflows, than outflows

Capital inflows: $17.9M | Capital outflows: $14.9M

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

1.09% more ownership

Funds ownership: 48.82% → 49.91% (+1.1%)

2% less funds holding

Funds holding: 91 → 89 (-2)

Holders
89
Holders Change
-2
Holders Change %
-2.2%
% of All Funds
2.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
31
Reduced
23
Closed
14
Calls
$1.7​M
Puts
$537​K
Net Calls
+$1.17​M
Net Calls Change
+$1.14​M

TTPH Hedge Fund Activity: Q1 2017 in Review

89 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals (TTPH) for Q1 2017, worth a combined $170M — up 134% from $72.6M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new TTPH positions and 14 closed out — a net gain of 2 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was Tekla Capital Management, adding an estimated $4.55M. The largest seller was Wellington Management Group, cutting an estimated $4.68M.

  • 89 institutional investors held Tetraphase Pharmaceuticals (TTPH) as of Q1 2017, down from 91 in Q4 2016.
  • Funds reported $170M of Tetraphase Pharmaceuticals stock for Q1 2017, up 134% quarter-over-quarter.
  • 16 funds opened new Tetraphase Pharmaceuticals positions in Q1 2017 and 14 closed out, a net change of +2 holders.
  • The largest Tetraphase Pharmaceuticals buyer in Q1 2017 was Tekla Capital Management, an estimated $4.55M added.
  • The largest Tetraphase Pharmaceuticals seller in Q1 2017 was Wellington Management Group, an estimated $4.68M sold.

Based on aggregated 13F filings for Q1 2017.